# CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

> **NCT04843839** · PHASE2 · UNKNOWN · sponsor: **L.V. Prasad Eye Institute** · enrollment: 30 (estimated)

## Conditions studied

- Congenital Hereditary Endothelial Dystrophy of Cornea

## Interventions

- **DRUG:** Nepafenac 0.1% Oph Susp
- **DRUG:** Refresh Tears 0.5% Lubricant Eye Drops

## Key facts

- **NCT ID:** NCT04843839
- **Lead sponsor:** L.V. Prasad Eye Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-15
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04843839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04843839, "CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT04843839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*